

**THE STATE EDUCATION DEPARTMENT** / THE UNIVERSITY OF THE STATE OF NEW YORK / ALBANY, NY 12234

TO:	The Professional Practice Committee
FROM:	Frank Muñoz
SUBJECT:	Conceptual Discussion of Possible Amendments to the Rules of the Board of Regents Relating to Prescriptions
DATE:	January 24, 2011

## AUTHORIZATION(S):

## **Summary**

### Issue for Discussion

The purpose of this item is to discuss with the Professional Practice Committee proposals relating to (1) the information to be included on prescription forms issued by physicians and other prescribers, and (2) customized patient medication packaging, which is intended to increase patient compliance with complex medication regimens.

### Reason(s) for Consideration

Review of Policy.

### Proposed Handling

This item is intended to bring to the attention of the Professional Practice Committee emerging issues that have been brought to our attention by the Department of Health and others through conversations with the Board of Pharmacy. Adoption of these proposals would require amendments to the Rules of the Board of Regents.

### **Background Information**

### **Prescription Forms**

Section 29.7(a)(1) of the Rules of the Board of Regents specifies the information that must be provided on every prescription. That information currently includes the name, address, and age of the patient; the strength and quantity of the drug; directions for use; and the name, address, telephone number, profession, and signature of the prescriber.

The State Board of Pharmacy is now recommending that every prescription written in this State be required to include the prescriber's National Provider Identifier (NPI). The NPI is the unique provider identifier required by the federal Health Insurance Portability and Accountability Act (HIPAA). It is used in many prescription drug benefit programs administered by the Department of Health or offered by other providers for a variety of purposes, including validation of the provider's license and quality of care initiatives. The preprint of the individual NPI number on the prescription form will allow pharmacies to easily obtain the NPI for claims submission purposes. In the past, many programs inappropriately used prescribers' Drug Enforcement Administration (DEA) numbers to identify prescribers. In addition to the fact that it was never intended that the DEA number to be used for this purpose, many professionals do not choose to obtain a DEA number, and other prescribers are not eligible for a DEA number. It was for these reasons that the NPI process was developed.

While engaging in discussions on the NPI, the State Board of Pharmacy and others suggested a concurrent amendment to allow a reformatting of prescription blanks to include a space for the voluntary inclusion of a diagnosis or diagnostic code. Medical errors are estimated to cause as many as 100,000 premature deaths each year. Although medication errors represent a small percentage of all errors, the prescribing, dispensing and administration of incorrect drugs can have devastating, even fatal, results. Unfortunately, with many thousands of drug products on the market, the number of look-alike and sound-alike (LASA) drugs often contribute to these errors. For reference, we have attached a chart of these LASA combinations compiled by the Institute for Safe Medication Practices, keyed to show the very different indications for each (Attachment A). Interestingly, the Medicare and Medicaid programs already require that prescriptions for durable medical equipment contain a diagnosis.

As indicated, these concepts have been broadly discussed. These discussions have included participation by associations representing pharmacists and physicians, as well as the New York State Department of Health. Underscoring the importance of these concepts, we have attached a letter from former Commissioner of Health Richard Daines expressing the Department of Health's support for these concepts (Attachment B).

### Customized Patient Packaging

The second proposal being presented for your consideration concerns a method of packaging drugs that is officially referred to as customized patient packaging by the United States Pharmacopeia (USP), the official compendia of standards for drugs in the United States.

In traditional packaging for tablets and capsules, each drug is placed in a vial with a label. An alternative method is unit-dose packaging, in which each capsule or tablet is packaged separately. Customized patient medication packaging is different in that several different drugs are packaged together for administration at the same time of day. Specific labeling would still be required, and certain drugs, such as those that are controlled substances or those that are known to be chemically unstable, would not be permitted in this type of packaging. Likewise, to assure the chemical and therapeutic viability of these medications, once packaged, repackaging would be prohibited, and the

customized patient medication packages would have a 60-day expiration period. To provide additional background information, the USP Guidelines for customized patient packaging are attached (Attachment C).

Customized patient medication packaging would not be appropriate for all patients. It has been proven, however, to increase compliance with complex therapeutic regimens, such as those required for patients with end-stage renal disease or HIV/AIDS. In all cases, it is anticipated that providers, patients, and caregivers will be familiarized with the process and the packaging itself. Customized patient medication packaging may reduce reliance on daily and weekly "pill-minders" that are often packed by patients themselves or by caregivers, with a potential for error that this customized patient packaging would avoid.

### Timetable for Implementation

If the concept is approved by the Professional Practice Committee, amendments to the Rules of the Board of Regents will be presented for action later this year.

# STATE OF NEW YORK DEPARTMENT OF HEALTH

Corning Tower The Governor Nelson A. Rockefeller Empire State Plaza Albany, New York 12237

Richard F. Daines, M.D. Commissioner

James W. Clyne, Jr. Executive Deputy Commissioner

November 12, 2010

Lawrence H. Mokhiber Executive Secretary, State Board of Pharmacy Office of the Professions State Education Building, 2<sup>nd</sup> Floor 89 Washington Avenue Albany, New York 12234

Dear Mr. Mokhiber:

We were pleased to learn that the State Board of Pharmacy is considering the addition of the individual National Provider Identifier (NPI) and a space for Diagnosis Code on New York State official prescription forms. This letter reflects the support of the New York State Department of Health (Department) for these changes.

As you know, the Department administers prescription drug benefits to over five million New Yorkers through New York Medicaid, Child Health Plus, and the Elderly Prescription Insurance Coverage Program (EPIC). As the unique provider identifier required by the Health Insurance Portability and Accountability Act (HIPAA), the individual NPI is used in these programs for a variety of claim system edits, including validation of the provider's license and quality of care initiatives. The preprint of the individual NPI number on the prescription form for those prescribers who are covered under HIPAA will allow pharmacies to easily obtain the NPI for claims submission purposes and serves the same purposes as did the preprint of the prescriber's license number. Under this proposal, prescribers who are not subject to HIPAA will not be obligated, but may voluntarily provide their individual NPI on prescriptions.

The Department also supports the voluntary submission of diagnosis code(s) by the prescriber on the prescription form as a way to reduce the risk of medication errors. Diagnosis code is currently a requirement for prescription claims submitted under Medicare Part B and for most claims submitted to Medicaid. In addition to avoiding potential adverse events, the inclusion of a space on the prescription form for the voluntary submission of diagnosis code(s) will reduce the administrative burden and cost of follow-up with beneficiaries and/or providers when this information is needed.

Thank you for the opportunity to submit the Department's views on these important issues. Please contact Dr. James Figge at (518) 474-8045 if we can be of further assistance.

Sincerely,

IF. Vaini

Richard F. Daines, M.D. Commissioner of Health

cc: Donna Frescatore Gregory S. Allen Janet Elkind James Figge, M.D., M.B.A. John Morley, M.D. to the product where it has been repackaged in a different container, repackaged drugs dispensed pursuant to a prescription are exempt from this expiration date labeling requirement. It is necessary, therefore, that other precautions be taken by the dispenser to preserve the strength, quality, and purity of drugs that are repackaged for ultimate distribution or sale to patients. The following guidelines and requirements are applicable where

The following guidelines and requirements are applicable where official dosage forms are repackaged into single-unit or unit-dose containers or mnemonic packs for dispensing pursuant to prescription.

Labeling-It is the responsibility of the dispenser, taking into account the nature of the drug repackaged, any packaging and beyond-use dating information in the manufacturer's product labeling, the characteristics of the containers, and the storage conditions to which the article may be subjected, to place a suitable beyond-use date on the label. Repackaged dosage forms must bear on their labels beyond-use dates as determined from information in the product labeling. In the absence of stability data or information to the contrary, such date should not exceed (1) 25% of the remaining time between the date of repackaging and the expiration date on the original manufacturer's bulk container, or (2) a six-month period from the date the drug is repackaged, whichever is earlier. Each single-unit or unit-dose container bears a separate label, unless the device holding the unit-dose form does not allow for the removal or separation of the intact single-unit or unit-dose container therefrom.

**Storage**—Store the repackaged article in a humidity-controlled environment and at the temperature specified in the individual monograph or in the product labeling. Where no temperature or humidity is specified in the monograph or in the labeling of the product, controlled room temperature and a relative humidity corresponding to 75% at 23° are not to be exceeded during repackaging or storage.

A refrigerator or freezer shall not be considered to be a humiditycontrolled environment, and drugs that are to be stored at a cold temperature in a refrigerator or freezer shall be placed within an outer container that meets the monograph requirements for the drug contained therein.

#### CUSTOMIZED PATIENT MEDICATION PACKAGES

In lieu of dispensing two or more prescribed drug products in separate containers, a pharmacist may, with the consent of the patient, the patient's caregiver, or a prescriber, provide a customized patient medication package (patient med pak).<sup>7</sup>

A patient med pak is a package prepared by a pharmacist for a specific patient comprising a series of containers and containing two or more prescribed solid oral dosage forms. The patient med pak is so designed or each container is so labeled as to indicate the day and time, or period of time, that the contents within each container are to be taken.

It is the responsibility of the dispenser to instruct the patient or caregiver on the use of the patient med pak.

Label---

(A) The patient med pak shall bear a label stating:

(1) the name of the patient;

(2) a serial number for the patient med pak itself and a separate identifying serial number for each of the prescription orders for each of the drug products contained therein;

(3) the name, strength, physical description or identification, and total quantity of each drug product contained therein;

(4) the directions for use and cautionary statements, if any, contained in the prescription order for each drug product therein;

(5) any storage instructions or cautionary statements required by the official compendia;

(6) the name of the prescriber of each drug product;

(7) the date of preparation of the patient med pak and the beyond-use date or period of time assigned to the patient med pak (such beyond-use date or period of time shall be not longer then

<sup>7</sup> It should be noted that there is no special exemption for patient med paks from the requirements of the Poison Prevention Packaging Act. Thus the patient med pak, if it does not meet child-resistant standards, shall be placed in an outer package that does comply, or the necessary consent of the purchaser or physician, to dispense in a container not intended to be child-resistant, shall be obtained. the shortest recommended beyond-use date for any dosage form included therein or not longer than 60 days from the date of preparation of the patient med pak and shall not exceed the shortest expiration date on the original manufacturer's bulk containers for the dosage forms included therein); alternatively, the package label shall state the date of the prescription(s) or the date of preparation of the patient med pak, provided the package is accompanied by a record indicating the start date and the beyond-use date;

(8) the name, address, and telephone number of the dispenser (and the dispenser's registration number where necessary); and

(9) any other information, statements, or warnings required for any of the drug products contained therein.

(B) If the patient med pak allows for the removal or separation of the intact containers therefrom, each individual container shall bear a label identifying each of the drug products contained therein.

Labeling—The patient med pak shall be accompanied by a patient package insert, in the event that any medication therein is required to be dispensed with such insert as accompanying labeling. Alternatively, such required information may be incorporated into a single, overall educational insert provided by the pharmacist for the total patient med pak.

**Packaging**—In the absence of more stringent packaging requirements for any of the drug products contained therein, each container of the patient med pak shall comply with the moisture permeation requirements for a Class B single-unit or unit-dose container (see *Containers*—*Permeation* (671)). Each container shall be either not reclosable or so designed as to show evidence of having been opened.

Guidelines—It is the responsibility of the dispenser, when preparing a patient med pak, to take into account any applicable compendial requirements or guidelines and the physical and chemical compatibility of the dosage forms placed within each container, as well as any therapeutic incompatibilities that may attend the simultaneous administration of the medications. In this regard, pharmacists are encouraged to report to USP headquarters any observed or reported incompatibilities.

**Recordkeeping**—In addition to any individual prescription tiling requirements, a record of each patient med pak shall be made and filed. Each record shall contain, as a minimum:

(1) the name and address of the patient;

(2) the serial number of the prescription order for each drug product contained therein;

(3) the name of the manufacturer or labeler and lot number for each drug product contained therein;

(4) information identifying or describing the design, characteristics, or specifications of the patient med pak sufficient to allow subsequent preparation of an identical patient med pak for the patient;

(5) the date of preparation of the patient mod pak and the beyond-use date that was assigned;

(6) any special labeling instructions; and

(7) the name or initials of the pharmacist who prepared the patient med pak.

## 

The tests that follow are provided to determine the moisture permeability of containers utilized for drugs being dispensed on prescription. The section Multiple-unit Containers for Capsules and Tablets applies to multiple-unit containers (see Preservation, Packaging, Storage, and Labeling under General Notices). The section Single-unit Containers and Unit-dose Containers for Capsules and Tablets applies to single-unit and unit-dose containers (see Singleunit Containers and Unit-dose Containers for Nonsterile Solid and Liquid Dosage Forms under Containers (661)). As used herein, the term "container" refers to the entire system comprising, usually, the container itself, the liner (if used), the closure in the case of multiple-unit containers, and the lidding and blister in the case of single-unit and unit-dose containers.

Where the manufacturer's unopened multiple-unit, single-unit, or unit-dose packages are used for dispensing the drug, such containers are exempt from the requirements of this test.

his list of confused drug names, which includes look-alike and sound-alike name pairs, consists of those name pairs that have been involved in medication errors published in the *ISMP Medication Safety Alert*? and the *ISMP Medication Safety Alert*? Community/Ambulatory Care Edition. The errors involving these medications were reported to ISMP through the ISMP Medication Errors Reporting Program (MERP). This list also contains the names that appear on The Joint Commission's list of look-alike and sound-alike names. The Joint Commission established a National Patient Safety Goal that requires each accredited organization to identify a list of look-alike or soundalike drugs used in the organization. Those names that appear on The Joint Commission's list have been noted with an asterisk (\*) below.

Drug Name	Confused Drug Name	Drug Name	Confused Drug Name
Abelcet*	amphotericin B*	amLODIPine	aMILoride
Accupril	Aciphex	amphotericin B*	Abelcet*
acetaZOLAMIDE*	acetoHEXAMIDE*	amphotericin B*	Ambisome*
acetic acid for irrigation	glacial acetic acid	Anacin	Anacin-3
acetoHEXAMIDE*	acetaZOLAMIDE*	Anacin-3	Anacin
Aciphex	Accupril	antacid	Atacand
Aciphex	Aricept	Antivert	Axert
Activase	Cathflo Activase	Anzemet	Avandamet
Activase	TNKase	Apresoline	Priscoline
Actonel	Actos	argatroban	Aggrastat
Actos	Actonel	argatroban	Orgaran
Adacel (Tdap)	Daptacel (DTaP)	Aricept	Aciphex
Adderall	Inderal	Aricept	Azilect
Adderall	Adderall XR	- aripiprazole	proton pump inhibitors
Adderall XR	Adderall	aripiprazole	rabeprazole
Advair*	Advicor*	Asacol	Os-Cal
Advicor*	Advair*	Atacand	antacid
Advicor	Altocor	Atrovent	Natru-Vent
Afrin (oxymetazoline)	Afrin (saline)	Avandamet	Anzemet
Afrin (saline)	Afrin (oxymetazoline)	Avandia	Prandin
Aggrastat	argatroban	Avandia*	Coumadin*
Aldara	Alora	AVINza	INVanz
Alkeran	Leukeran	AVINza*	Evista*
Alkeran	Myleran	Axert	Antivert
Allegra	Viagra	azaCITIDine	azaTHIOprine
Alora	Aldara	aza <b>THIO</b> prine	azaCITIDine
ALPRAZolam*	LORazepam*	Azilect	Aricept
Altocor	Advicor	B & O (belladonna and opium)	Beano
amantadine	amiodarone	BabyBIG	HBIG (hepatitis B immune globulin)
Amaryl	Reminyl	Bayhep-B	Bayrab
Ambisame*	amphotericin B*	Bayhep-B	Bayrho-D
Amicar*	Omacor*	Bayrab	Bayhep-B
Amikin	Kineret	Bayrab	Bayrho-D
aMILoride	amLODIPine	Bayrho-D	Bayhep-B
amiodarone	amantadine	Bayrho-D	Bayrab

\* These drug names are included on The Joint Commission's list of look-alike or sound-alike drug names from which an accredited organization creates it own list to satisfy the requirements of the National Patient Safety Goals. Visit <u>every point commission are</u> for more information about this Joint Commission requirement.

Permission is granted to reproduce material for internal newsletters or communications with proper attribution. Other reproduction is prohibited without written permission. Unless noted, reports were received through the ISMP Medication Errors Reporting Program (MERP). Report actual and potential medication errors to the MERP via the web at <u>wew.isona.org/memp</u> or by calling 1-800-FAIL-SAF(E). ISMP is a federally certified patient safety organization (PSD), providing legal protection and confidentiality for patient safety data and error reports it receives.

Institute for Safe Medication Practices

Drug Name	Confused Drug Name	Drug Name	Confused Drug Name
Beano	B & O (belladonna and opium)	Clindesse	Clindets
Benadryl	benazepril	Clindets	Clindesse
benazepril	Benadryl	clomiPHENE	clomiPRAMINE
Benicar	Mevacor	clomiPRAMINE	clomiPHENE
Betadine (with providone-iodine)	Betadine (without providone-iodine)	clonazePAM	cloNIDine
Setadine (without providone-iodine)	Betadine (with providone-iodine)	clonazePAM	LORazepam
Bextra	Zetia	cloNIDine	clonazePAM
Bicillin C-R	Bicillin L-A	cloNIDine*	Klono <b>PIN*</b>
Bicillin L-A	Bicillin C-R	Clozaril	Colazai
Bicitra	Polycitra	Coagulation factor IX (recombinant)	Factor IX Complex, Vapor Heated
Brethine	Methergine	codeine	Lodine
Brevibloc	Brevital	Colace	Cozaar
Brevital	Brevibloc	Colazal	Clozaril
bu <b>PROP</b> ion	busPIRone	colchicine	Cortrosyn
busPIRone	bu <b>PROP</b> ion	Corrivax	Recombivax HB
Capadex [non-US product]	Kapidex	Cortrosyn	colchicine
Capex	Kapidex	Coumadin*	Avandia*
Carac	Kuric	Coumadin*	Cardura*
captopril	carvedilol	Cozaar	Colace
car <b>BAM</b> azepine	OXcarbazepine	Cozaar	Zocor
CARBOplatin	CISplatin	cycloSERINE	cycloSPORINE
Cardura*	Coumadin*	cycloSPORINE	cycloSERINE
carvedilol	captopril	Cymbalta	Symbyax
Casodex	Kapidex	DACTINomycin	DAPTOmycin
Cathflo Activase	Activase	Daptacel (DTaP)	Adacel (Tdap)
Cedax	Cidex	DAPT0mycin	DACTINomycin
ce <b>FAZ</b> olin	cefTRIAXone	Darvocet*	Percocet*
cefTRIAXone	ce <b>FAZ</b> olin	Darvon	Diovan
CeleBREX*	CeleXA*	DAUNOrubicin*	DAUNOrubicin citrate liposomal*
CeleBREX*	Cerebyx*	DAUNOrubicin*	DOXOrubicin*
CeleXA	ZyPREXA	DAUNOrubicin*	IDArubicin*
CeleXA*	CeleBREX*	DAUNOrubicin citrate liposomal*	DAUNOrubicin*
CeleXA*	Cerebyx*	Denavir	indinavir
Cerebyx*	CeleBREX*	Depakote	Depakote ER
Cerebyx*	CeleXA*	Depakote ER	Depakote
cetirizine	sertraline	Depo-Medrol	Solu-MEDROL
chlordiazePOXIDE	chlorproMAZINE	Depo-Provera	Depo-subQ provera 104
chlorproMAZINE	chlordiazePOXIDE	Depo-subQ provera 104	Depo-Provera
chlorproMAZINE	chlorproPAMIDE	desipramine	disopyramide
chlorproPAMIDE	chlorproMAZINE	dexmethylphenidate	methadone
Cidex	Cedax	Diabenese	Diamox
CISplatin	CARBOplatin	Diabeta*	Zebeta*
Claritin (loratadine)	Claritin Eye (ketotifen furnarate)	Diamox	Diabenese
Claritin-D	Claritin-D 24	Diflucan*	Diprivan*
Claritin-D 24	Claritin-D	Dilacor XR	Pilocar
Claritin Eye (ketotifen fumarate)	Claritin (loratadine)	Dilaudid	Dilaudid-5

\* These drug names are included on The Joint Commission's list of look-alike or sound-alike drug names from which an accredited organization creates it own list to satisfy the requirements of the National Patient Safety Goals. Visit was gaint commission org for more information about this Joint Commission requirement.

Permission is granted to reproduce material for internal newsletters or communications with proper attribution. Other reproduction is prohibited without written permission. Unless noted, reports were received through the ISMP Medication Errors Reporting Program (MERP). Report actual and potential medication errors to the MERP via the web at <u>were semicarg/memo</u> or by calling 1-800-FAIL-SAF(E). ISMP is a federally certified patient safety organization (PSD), providing legal protection and confidentiality for patient safety data and error reports it receives.

Medication Practices

Drug Name	Confused Drug Name	Drug Name	Confused Drug Name
Dilaudid-5	Dilaudid	Fiorinal	Fioricet
dimenhyDRINATE	diphenhydrAMINE	flavoxate	fluvoxamine
diphenhydrAMINE	dimenhyDRINATE	Flonase	Flovent
Dioval	Diovan	Flovent	Flonase
Diovan	Dioval	flumazenil	influenza virus vaccine
Diovan	Zyban	FLUoxetine	PARoxetine
Diovan	Darvon	FLUoxetine	DULoxetine
Diprivan*	Diflucan*	fluvoxamine	flavoxate
Diprivan	Ditropan	Folex	Foltx
disopyramide	desipramine	folic acid*	folinic acid (leucovorin calcium)*
Ditropan	Diprivan	folinic acid (leucovorin calcium)*	folic acid*
DOBUTamine	DOPamine	Foltx	Folex
DOPamine	DOBUTamine	fomepizole	omeprazole
Doxil	Paxil	Foradil	Fortical
DOXOrubicin*	DAUNOrubicin*	Foradil	Toradol
DOXOrubicin*	DOXOrubicin liposomal*	Fortical	Foradil
DOXOrubicin*	IDArubicin*	gentamicin	gentian violet
DOXOrubicin liposomal*	DOXOrubicin*	gentian vio <del>le</del> t	gentamicin
Dułcolax (bisacodyl)	Dulcolax (docusate sodium)	glacial acetic acid	acetic acid for irrigation
Dulcolax (docusate sodium)	Dulcolax (bisacodyl)	glipiZIDE	glyBURIDE
DULoxetine	FLUoxetine	glyBURIDE	glipiZIDE
Durasal	Durezol	Granulex	Regranex
Durezol	Durasal	guaiFENesin	guanFACINE
Duricef	Ultracet	guanFACINE	guaiFENesin
Dynacin	Dynacirc	HBIG (hepatitis B immune globulin)	BabyBIG
Dynacirc	Dynacin	Healon	Hyalgan
edetate calcium disodium	edetate disodium	heparin*	. Hespan*
edetate disodium	edetate calcium disodium	Hespan*	heparin*
Effexor*	Effexor XR*	HMG-CoA Reductase Inhibitors ("statins")	nystatin
Effexor XR*	Effexor*	HumaLOG*	HumuLIN*
Enbrel	Levbid	HumaLOG*	NovoLOG*
Engerix-B adult	Engerix-B pediatric/adolescent	HumaLOG Mix 75/25	Humu <b>LIN</b> 70/30
Engerix-B pediatric/adolescent	Engerix-B adult	Humapen Memoir (for use with HumaLOG)	Humira Pen
Enjuvia	Januvia	Humira Pen	Humapen Memoir (for use with HumaLO
ePHEDrine*	EPINEPHrine*	HumuLIN*	NovoLIN*
EPINEPHrine*	ePHEDrine*	Humu <b>LIN</b> *	HumaLOG*
Estratest	Estratest HS	HumuLIN 70/30	HumaLOG Mix 75/25
Estratest HS	Estratest	Hyakgan	Healon
ethambutol	Ethmozine	hydrALAZINE*	hydr <b>OXY</b> zine*
Ethmozine	ethambutol	HYDROcodone*	DXYCODONE*
Evista*	AVINza*	Hydrogesic	hydr <b>OXY</b> zine
Factor IX Complex, Vapor Heated	Coagulation factor IX (recombinant)	HYDROmorphone*	morphine*
Femara	Fembrt	hydr <b>OXY</b> zine	Hydrogesic
Fembrit	Femara	hydr <b>OXY</b> zine*	hydrALAZINE*
fenta <b>NYL</b>	SUFentani	IDAnubicin*	DAUNOrubicin*

\* These drug names are included on The Joint Commission's list of look-alike or sound-alike drug names from which an accredited organization creates it own list to satisfy the requirements of the National Patient Safety Goals. Visit <u>wave joint commission org</u> for more information about this Joint Commission requirement.

Permission is granted to reproduce material for internal newsletters or communications with proper attribution. Other reproduction is prohibited without written permission. Unless noted, reports were received through the ISMP Medication Errors Reporting Program (MERP). Report actual and potential medication errors to the MERP via the web at <u>www.sma.org/man.</u> or by calling 1-800-FAIL-SAF(E). ISMP is a federally certified patient safety organization (PSO), providing legal protection and confidentiality for patient safety data and error reports it receives.


Institute for Safe Medication Practices www.ismp.org

Orug Name	Confused Drug Name	Drug Name	Confused Drug Name
Inderal	Adderall	Laniam	Levaquin
indinavir	Denavir	Lasix	Luvox
in <b>FLIX</b> imab	ri <b>TUX</b> imab	Lente	Lantus
influenza virus vaccine	a flumazenil	leucovorin calcium*	Leukeran*
influenza virus vaccine	tuberculin purified protein derivative (PPD)	Leukeran	Alkeran
Inspra	Spiriva	Leukeran	Myleran
INVanz	AVINza	Leukeran*	leucovorin calcium*
iodine	Lodine	Levaquin	Lariam
Isordil	Plendil	Levbid	Enbrel
isotretinoin	tretinoin	levetiracetam	levofloxacin
Jantoven	Janumet	levofloxacin	levetiracetam
Jantoven	Januvia	levothyroxine	larno <b>TRI</b> gine
Janumet	Jantoven	levothyroxine	Lanoxin
Janumet	Januvia	Lexapro	Loxitane
Janumet	Sinemet	Lipitor	Loniten
Januvia	Enjuvia	Lipitor	ZyrTEC
Januvia	Jantoven	lithium carbonate	lanthanum carbonate
Januvia	Janumet	Lodine	codeine
K-Phos Neutral	Neutra-Phos-K	Lodine	iodine
opectate (bismuth subsalcylate)	Kaopectate (docusate calcium)	Loniten	Lipitor
Kaopectate (docusate calcium)	Kaopectate (bismuth subsalcylate)	Lopressor	Lyrica
Kadian	Kapidex	LORazepam*	ALPRAZolam*
Kaletra	Keppra	LORazepam	clonazePAM
Kapidex	Capadex [non-US product]	LORazepam	Lovaza
Kapidex	Capex	Lotronex	Protonix
Kapidex	Casodex	Lovaza	LORazepam
Kapidex	Kadian	Loxitane	Lexapro
Keflex	Keppra	Loxitane	Soriatane
Keppra	Kaletra	Lunesta	Neulasta
Keppra	Keflex	Lupron Depat-3 Month	Lupron Depot-Ped
Ketalar	ketorolac	Lupron Depot-Ped	Lupron Depot-3 Month
ketorolac	Ketalar	Luvox	Lasix
ketorolac	methadone	Lyrica	Lopressor
Kineret	Amikin	Maalox	Maalox Total Stomach Relief
Klono <b>PIN*</b>	cloNIDine *	Maalox Total Stomach Relief	Maalox
Kuric	Carac	Matulane	Matema
Kwell	Qwell	Materna	Matulane
LaMICtal	LamISIL	Maxzide	Microzide
LamISIL	LaMICtal	Menactra	Menomune
lami <b>VUD</b> ine*	lamoTRIgine*	Menomune	Menactra
lamoTRIgine*	lami¥U Dine*	Mephyton	methadone
lamo <b>TRI</b> gine	levothyroxine	Metadate	methadone
Lanoxin	levothyroxine	Metadate CD	Metadate ER
Lanoxín	naloxone	Metadate ER	Metadate CD
lanthanum carbonate	lithium carbonate	Metadate ER	methadone
Lantus	Lente	metFORMIN*	metroNIDAZOLE*

\* These drug names are included on The Joint Commission's list of look-alike or sound-alike drug names from which an accredited organization creates it own list to satisfy the requirements of the National Patient Safety Goals. Visit <u>www.jointcommission.org</u> for more information about this Joint Commission requirement.

Permission is granted to reproduce material for internal newsletters or communications with proper attribution. Other reproduction is prohibited without written permission. Unless noted, reports were received through the ISMP Medication Errors Reporting Program (MERP). Report actual and potential medication errors to the MERP via the web at <u>www.ismu.org/news</u> or by calling 1-800-FAIL-SAF(E). ISMP is a federally certified patient safety organization (PSD), providing legal protection and confidentiality for patient safety data and error reports it receives.

Institute for Safe Medication Practices www.ismp.org



Drug Mana	Confused Drug Name	Drug Name	Confused Drug Name
methadone	dexmethylphenidate	Neurontin	Noraxin
methadone	ketorolac	Neutra-Phos-K	K-Phos Neutral
methadone	Mephyton	NexAVAR	NexIUM
methadone	Metadate	Nexi U M	NexAVAR
methadone	Metadate ER	ni <b>CARdipin</b> e	NIFEdipine
methadone	methylphenidate	NIFEdipine	niCARdipine
Methergine	Brethine	NIFEdipine	niMODipine
methimazole	metolazone	niMODipine	NIFEdipine
methylphenidate	methadone	Norcuron	Narcan
metolazone	methimazole	Normodyne	Norpramin
metoprolol succinate	metoprolol tartrate	Noroxin	Neurontin
metoprolol tartrate	metoprolol succinate	Norpramin	Normodyne
metroNIDAZOLE*	metFORMIN*	Norvasc	Navane
Mevacor	Benicar	NovoLIN*	Humu <b>LIN*</b>
Micronase	Microzide	NovoLIN*	NovoLDG*
Microzide	Marzide	NovoLIN 70/30*	NovoLOG Mix 70/30*
Microzide	Micronase	NovoLOG*	HumaLOG*
midodrine	Midrin	NovoLOG*	NovoLIN*
Midrin	midadrine	NovoLOG FLEXPEN	NovoLOG Mix 70/30 FLEXPEN
mifepristone		NovoLOG Mix 70/30 FLEXPEN	NovoLOG FLEXPEN
	misoprostol	NovoLOG Mix 70/30*	NovoLIN 70/30*
Miralax	Mirapex Miralax		HMG-CoA Reductase Inhibitors ("statins")
Mirapex		nystatin Occlusal-HP	Ocufiox
misoprostol	mifepristone	Ocuflox	Occlusal-HP
morphine*	HYDROmorphone*		
morphine - non-concentrated oral liquid*	morphine - oral liquid concentrate*	OLANZapine	QUEtiapine
morphine - oral liquid concentrate*	morphine - non-concentrated oral liquid*	Omacor*	Amicar*
Motrin	Neurontin	omeprazole	fomepizole
MS Contin*	DxyCONTIN*	opium tincture*	paregoric (camphorated tincture of opium)
Mucinex*	Mucomyst*	Oracea	Orencia
Mucinex D	Mucinex DM	Orencia	Oracea
Mucinex DM	Mucinex D	Orgaran	argatroban
Mucomyst*	Mucinex*	Ortho Tri-Cyclen	Ortho Tri-Cyclen LO
Myleran	Alkeran	Ortho Tri-Cyclen LO	Ortho Tri-Cyclen
Myleran	Leukeran	Os-Cal	Asacol
naloxone	Lanoxin	OXcarbazepine	carBAMazepine
Narcan	Norcuron	oxyCODONE*	HYDROcodone*
Natru-Vent	Atrovent	oxyCDDONE*	Oxy <b>CONTIN*</b>
Navane	Norvasc	Oxy <b>contin*</b>	MS Contin*
Neo-Synephrine (oxymetazoline)	Neo-Synephrine (phenylephrine)	Oxy <b>contin*</b>	oxyCODONE*
Neo-Synephrine (phenylephrine)	Neo-Synephrine (oxymetazoline)	paclitaxel	paclitaxel protein-bound particles
Neulasta	Lunesta	paclitaxel protein-bound particles	paclitaxel
Neulasta	Neumega	Pamelor -	Pantor DC
Neumega	Neupogen	Pamelor	Tambocor
Neumega	Neulasta	Panlor DC	Pamelor
Neupogen	Neumega	paregoric (camphorated tincture of opium)*	opium tincture*
Neurontin	Motrin	PARoxetine	FLUoxetine

CISMP 2010

\* These drug names are included on The Joint Commission's list of look-alike or sound-alike drug names from which an accredited organization creates it own list to satisfy the requirements of the National Patient Safety Goals. Visit <u>energiaintcommission org</u> for more information about this Joint Commission requirement.

Permission is granted to reproduce material for internal newsletters or communications with proper attribution. Other reproduction is prohibited without written permission. Unless noted, reports were received through the ISMP Medication Errors Reporting Program (MERP). Report actual and potential medication errors to the MERP via the web at <u>www.somo.org/mem.</u> or by calling 1-800-FAIL-SAF(E). ISMP is a federally certified patient safety organization (PSO), providing legal protection and confidentiality for patient safety data and error reports it receives.

Institute for Safe Medication Practices www.ismp.org

Drug Name	Confused Drug Name	Drug Name	Confused Drug Name
Patanol	Platinol	QUEtiapine	OLANZapine
Pavulon	Peptavlon	quiNIDine	quiNINE
Paxil	Doxil	quiNINE	qui <b>NID</b> ine
Paxil	Taxol	Qwell	Kwell
Paxil <sup>:</sup>	Plavix	rabeprazole	aripiprazole
pemetrexed	pralatrexate	Razadyne	Rozerem
Peptavion	Pavulon	Recombivax HB	Comvax
Percocet*	Darvocet*	Regranex	Granulex
Percocet	Procet	Reminyl	Robinul
PENTobarbital	PHENobarbital	Reminyl	Amaryt
PHENobarbital	PENTobarbital	Renagel	Renvela
Pilocar	Dilacor XR	Renvela	Renagel
Platinol	Patanol	Reprexain	ZyPREXA
Plavix	Paxil	Restoril	Risperdal
Plendil	Isordil	Retrovir*	ritonavir*
pneumococcal 7-valent vaccine	pneumococcal polyvalent vaccine	Rifadin	Rifater
pneumococcal polyvalent vaccine	pneumococcal 7-valent vaccine	Rifamate	rifampin
Polycitra	Bicitra	rifampin	Rifamate
pralatrexate	pemetrexed	rifampin	rifaximin
Prandin	Avandia	Rifater	Rifadin
Precare	Precose	rifaximin	rifampin
Precose	Precare	Risperdal	Restoril
prednisoLONE	predniSONE	risperidone	ropinirole
predniSONE	prednisoLONE	Ritalin	ritodrine
PriLOSEC*	PROzac*	Ritalin LA	Ritalin SR
Priscoline	Apresoline	Ritalin SR	Ritalin LA
probenecid	Procanbid	ritodrine	Ritalin
Procan SR	Procanbid	ritonavir*	Retrovir*
Procanbid	probenecid	nTUXimab	in <b>FLIX</b> imab
Procanbid	Procan SR	Robinul	Reminyl
Procardia XL	Protain XL	ropinirole	risperidone
Procet	Percocet	Roxanol	Roxicodone Intensol
Prograf	PROzac	Roxanol	Roxicet
propylthiouracil	Purinethol	Roxicet	Roxanol
Proscar	Provera	Roxicadone Intensol	Roxanol
Protain XL	Procardia XL	Rozerem	Razadyne
protamine	Protonix	Salagen	selegiline
proton pump inhibitors	aripiprazole	SandIMMUNE	SandoSTATIN
Protonix	Lotronex	SandoSTATIN	SandIMMUNE
Protonix	protamine	saquinavir	SINEquan
Provera	Proscar	saquinavir (free base)	saquinavir mesylate
Provera	PROzac	saquinavir mesylate	saquinavir (free base)
PROzac	Prograf	Sarafem	Serophene
PROzac*	PriLOSEC*	selegiline	Salagen
PROzac	Provera	Serophene	Sarafem
Purinethol	propylthiouracil	SEROquel	SEROquel XR

\* These drug names are included on The Joint Commission's list of look-alike or sound-alike drug names from which an accredited organization creates it own list to satisfy the requirements of the National Patient Safety Goals. Visit <u>reversion contraction</u> for more information about this Joint Commission requirement.

Permission is granted to reproduce material for internal newsletters or communications with proper attribution. Other reproduction is prohibited without written permission. Unless noted, reports were received through the ISMP Medication Errors Reporting Program (MERP). Report actual and potential medication errors to the MERP via the web at <u>www.smp.org/neup</u> or by calling 1-800-FAIL-SAF(E). ISMP is a federally certified patient safety organization (PSO), providing legal protection and confidentiality for patient safety data and error reports it receives.

est Institute for Safe Medication Practices www.ismp.org

Drug Name	Confused Drug Name	Drug Name	Confused Drug Name
SEROquel	Serzone	Testoderm	Testoderm with Adhesive
SERDquel	SINEquan	tetanus diptheria toxoid (Td)	tuberculin purified protein derivative (PPI
SEROquel XR	SEROquel	Thalomid	Thiamine
sertraline	cetirizine	Thiamìne	Thalomid
sertraline	Soriatane	tia <b>GAB</b> ine*	tiZANidine*
Serzone	SEROquel	Tiazac	Ziac
Sinemet	Janumet	Ticlid	Tequin
SINEquan	saquinavir	tiZANidine*	tia <b>GAB</b> ine*
SINEquan	SEROquel	TNKase	Activase
SINEquan	Singulair	TNKase	t-PA
SINEquan	Zonegran	Tobradex	Tobrex
Singulair	SINEquan	Tobrex	Tobradex
sita <b>GLIP</b> tin	SUMAtriptan	TOLAZamide	TOLBUTamide
Solu-CORTEF	Solu-MEDROL	TOLBUTamide	<b>TOLAZ</b> amide
Solu-MEDROL	Depo-Medrol	Topamax*	Toprol-XL*
Sołu-MEDROL	Solu-CORTEF	Toprol-XL*	Topamax*
Sonata	Soriatane	Toradol	Foradil
Soriatane	Loxitane	t-PA	TNKase
Soriatane	sertraline	Tracleer	Tricor
Soriatane	Sonata	tra <b>MAD</b> ol*	traZODone*
sotalol	Sudafed	traZODone*	tra <b>MADol*</b>
Spiriva	Inspra	TRENtal	TEGretol
Sudafed	sotalol	tretinoin	isotretinoin
Sudafed	Sudafed PE	Tricor	Trackeer
Sudafed PE	Sudafed	tromethamine	Trophamine
SUFentanil	fenta <b>NYL</b>	Trophamine	tromethamine
sulfADIAZINE	sulfiSOXAZOLE	tuberculin purified protein derivative (PPD)	influenza virus vaccine
sulfiSOXAZOLE	sulfADIAZINE	tuberculin purified protein derivative (PPD)	tetanus diptheria toxoid (Td)
SUMAtriptan	sitaGLIPtin	Tylenol	Tylenol PM
SUMAtriptan	zolmitriptan	Tylenol PM	Tylenol
Symbyax	Cymbalta	Ultracet	Dunicef
Tambocor	Pamelor	valacyclovir	valganciclovir
Taxol	Taxotere	Valcyte	Valtrex
Taxol	Paxil	valganciclovir	valacyclovir
Taxotere	Taxol	Valtrex	Valcyte
TEGretol	TEGretol XR	Varivax	VZIG (varicella-zoster immuneglobulin)
TEGretol	Tequin	Vesanoid	Vesicare
TEGretol	TRENtal	Vesicare	Vesanoid
TEGretol XR	TEGretol	Vexol	Vosol
Tequin	TEGretol	Viagra	Allegra
Tequin	Ticlid	vinBLAStine*	vinCRIStine*
Testoderm TTS	Testoderm	vinCRIStine*	vin <b>BLASt</b> ine*
Testoderm TTS	Testoderm with Adhesive	Viokase	Viokase 8
Testoderm with Adhesive	Testoderm	Viokase 8	Viokase
Testoderm with Adhesive	Testoderm TTS	Vioxx	Zyvox
Testoderm	Testoderm TTS	Viracept	Viramune

\* These drug names are included on The Joint Commission's list of look-alike or sound-alike drug names from which an accredited organization creates it own list to satisfy the requirements of the National Patient Safety Goals. Visit wave joint commission or for more information about this Joint Commission requirement.

Permission is granted to reproduce material for internal newsletters or communications with proper attribution. Other reproduction is prohibited without written permission. Unless noted, reports were received through the ISMP Medication Errors Reporting Program (MERP). Report actual and potential medication errors to the MERP via the web at <u>www.isma.org/merg</u> or by calling 1-800-FAIL-SAF(E). ISMP is a federally certified patient safety organization (PSO), providing legal protection and confidentiality for patient safety data and error reports it receives.

Medication Practices

Orug Name	Confused Drug Name	Drug Name	Confused Drug Name
Viramune	Viracept	Zocor	Cozaar
Vosol	Vexol	Zocor*	ZyrTEC*
VZIG (varicella-zoster immuneglobulin)	Varivax	zolmitriptan	SUMAtriptan
Wellbutrin SR*	Wellbutrin XL*	Zonegran	SINEquan
Wellbutrin XL*	Wellbutrin SR*	Zostrix	Zovirax
Xanax*	Zantac*	Zovirax	Zyvox
Xeloda	Xenical	Zovirax	Zostrix
Xenical	Xeloda	Zyban	Diovan
Yasmin	Yaz	ZyPREXA	CeleXA
Yaz	Yasmin	ZyPREXA	Reprexain
Zantac*	Xanax*	ZyPREXA*	Zestril*
Zantac*	ZyrTEC*	ZyPREXA*	Zyr <b>TEC*</b>
Zebeta*	Diabeta*	ZyPREXA Zydis	Zelapar (Zydis formulation)
Zebeta	Zetia	ZyrTEC	Lipitor
Zegerid	Zestril	ZyrTEC*	Zantac*
Zelapar (Zydis formulation)	ZyPREXA Zydis	ZyrTEC*	Zocor*
Zestril	Zegerid	ZyrTEC*	ZyPREXA*
Zestrit*	Zetia*	ZyrTEC	Zyr <b>TEC-</b> D
Zestril*	ZyPREXA*	ZyrTEC (cetirizine)	ZyrTEC Itchey Eye Drops (ketotifen fumarate)
Zetia	Bextra	Zyr <b>TEC</b> -D	ZyrTEC
Zetia	Zebeta	ZyrTEC Itchey Eye Drops (ketotifen fumarate)	ZyrTEC (cetirizine)
Zetia*	Zestril*	Zyvox	Vioxx
Ziac	Tiazac	Zyvox	Zovirax

\* These drug names are included on the The Joint Commission's list of look-alike or sound-alike drug names from which an accredited organization creates it own list to satisfy the requirements of the National Patient Safety Goals. Visit www.pintcommission.org for more information about this Joint Commission requirement.

Permission is granted to reproduce material for internal newsletters or communications with proper attribution. Other reproduction is prohibited without written permission. Unless noted, reports were received through the ISMP Medication Errors Reporting Program (MERP). Report actual and potential medication errors to the MERP via the web at <u>www.smp.org/memp</u> or by calling 1-800-FAIL-SAF(E). ISMP is a federally certified patient safety organization (PSO), providing legal protection and confidentiality for patient safety data and error reports it receives.

Institute for Safe Medication Practices www.ismp.org